San Carlos, CA, United States of America

Rowchanak Pakdaman

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 164(Granted Patents)


Location History:

  • Foster City, CA (US) (2018)
  • San Carlos, CA (US) (2014 - 2022)

Company Filing History:


Years Active: 2014-2022

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Rowchanak Pakdaman

Introduction

Rowchanak Pakdaman is a notable inventor based in San Carlos, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiviral compounds. With a total of 8 patents to his name, Pakdaman's work has the potential to impact the treatment of viral infections.

Latest Patents

Among his latest patents is a combination formulation of three antiviral compounds. This patent discloses pharmaceutical compositions that comprise an effective amount of velpatasvir, sofosbuvir, and voxilaprevir. The methods of use for this pharmaceutical composition are also outlined, showcasing the innovative approach Pakdaman has taken in addressing viral infections.

Career Highlights

Pakdaman has worked with prominent companies in the pharmaceutical industry, including Gilead Pharmasset LLC and Gilead Connecticut, Inc. His experience in these organizations has undoubtedly contributed to his expertise and success as an inventor.

Collaborations

Some of his notable coworkers include Dimitrios Stefanidis and Melissa Jean Casteel. Their collaboration has likely fostered an environment of innovation and creativity, further enhancing the development of groundbreaking pharmaceutical solutions.

Conclusion

Rowchanak Pakdaman's contributions to the field of antiviral pharmaceuticals demonstrate his commitment to innovation and improving healthcare outcomes. His patents reflect a deep understanding of complex pharmaceutical formulations, positioning him as a key figure in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…